BACKGROUND: Poor enrollment of adolescents and young adults (AYAs) (ages 15-39 years) onto cancer clinical trials (CCTs) may contribute to inferior survival gains compared with children. In this study, the authors assessed whether differences in CCT availability would explain lower CCT enrollment for early AYAs (eAYAs) (ages 15-21 years). METHODS: This prospective, observational cohort study was conducted at a single academic children's hospital. For consecutive patients who were newly diagnosed with cancer over a 13-month period, it was determined whether an appropriate CCT existed nationally or was available locally and whether enrollment on that CCT occurred. The proportions of eAYAs versus children in each category were compared using the chi-square test. The impact of age and other factors on enrollment status was assessed using logistic regression analysis. RESULTS: Among 216 patients, 58 were eAYAs, and 158 were children. There was no difference in the proportion of eAYAs versus children who had an existing CCT (28 of 58 In multivariable analysis, eAYAs were significantly less likely than children to be enrolled in an available CCT (adjusted odds ratio, 0.22; 95% confidence interval, 0.08-0.62). CONCLUSIONS: Equal proportions of children and eAYAs had CCTs available, but significantly fewer eAYAs were enrolled. These findings suggest that, for eAYAs, factors other than CCT availability are important enrollment barriers and should be addressed. Cancer 2018;124:983-90.
INTRODUCTION
Cancer remains the leading cause of disease-related death in the United States for adolescents and young adults (AYAs) (ages 15-39 years). Despite impressive survival gains achieved in both younger and older populations over the past 30 years, AYAs have not experienced the same improvements. 1 In 2006, the US National Cancer Institute (NCI) identified AYAs as a health-disparity population. 2 The lagging survival improvement of AYAs is multifactorial. [3] [4] [5] [6] [7] One fundamentally important contributor is the low participation of AYAs in NCI-sponsored cancer clinical trials (CCTs). Numerous studies of CCT enrollment indicate that from 40% to 60% of children aged <15 years participate in CCTs compared with only 10% to 20% of early AYAs (eAYAs) ages 15 to 21 years. 1, [8] [9] [10] [11] [12] For AYAs older than 21 years, the proportion participating is even lower. 10 This nonparticipation has serious consequences. Low CCT enrollment of AYAs has been directly correlated with significantly lower annual survival improvement compared with children. 12 Nonenrollment onto CCTs also prevents AYAs from gaining access to promising investigational therapies; providing biospecimens essential for basic and translational research; and benefiting from studies of supportive care, quality of life, cancer epidemiology, and other nonsurvival endpoints. 13 Reasons for lower CCT enrollment of AYAs are not well understood. Studies suggest that AYA enrollment barriers include suboptimal insurance, low socioeconomic status, distance to the cancer center, older age, type of cancer specialist, and treatment by community-based providers who do not participate in NCI-sponsored CCTs. 9, 14, 15 Limited availability of CCTs for AYAs is another potential factor often asserted to be of major importance. 9, 11, 16, 17 However, published data regarding CCT availability are scant and do not necessarily support this contention. 18 Availability of CCTs is a crucial consideration, because other factors that could influence enrollment, such as patient/family-level and provider-level issues, presuppose the availability of a CCT and are moot without one. 13 Yet an assessment of CCT availability is challenging, because it is difficult for retrospective studies to ascertain eligibility of individual patients for CCTs, which that commonly open and close to enrollment over time. Also, it is difficult for population-based studies to determine whether CCTs that existed nationally actually were open at specific treatment sites. To overcome these challenges, we undertook the current prospective study of consecutive eAYAs and children who were newly diagnosed with cancer to evaluate potential age-related differences in CCT availability and enrollment. The primary objective of the study was to compare the proportions of eAYAs and children for whom an appropriate CCT existed, was available locally, and was used for enrollment; secondary objectives were to evaluate the effects of age and other factors on CCT enrollment. Our overall hypothesis was that both availability of and enrollment onto CCTs would be significantly lower among eAYAs than among children.
MATERIALS AND METHODS

Study Design, Setting, and Case Ascertainment
This was a prospective, observational cohort study conducted at Children's Hospital Los Angeles (CHLA), an academic center located 6 miles from our affiliated, adultfocused cancer hospital. CHLA provides specialized cancer care from birth through young adulthood, typically up to age 21 years for newly diagnosed patients.
To confirm the feasibility of our methods, we first conducted an informal pilot study of 10 children and eAYAs who were not included in the cohort. For this study, all consecutive pathology reports from patients ages birth to 21 years were screened in real time by collaborating pediatric pathology fellows (H.T., J.S.) and then transmitted to the principal investigator (S.M.T.) with the patient's name, medical record number, and final pathology diagnosis. Pathology reports were reviewed by S.M.T. and were disregarded if they represented either pathology-only consultations for patients who did not receive cancer care at CHLA or second-surgery pathology specimens from patients who had already been included in this study. The remaining pathology reports were used to identify unique patients ages birth 0 to 21 years with a first diagnosis of cancer who had cancer treatment initiated at CHLA. Exclusion criteria were relapsed cancer, a subsequent malignant neoplasm, or transfers to CHLA in those who had started cancer treatment elsewhere.
For each patient who met eligibility criteria for this study, pertinent demographic (age, sex, and race/ethnicity) and disease-related (cancer diagnosis, stage, grade, risk group, and relevant genomics) information was abstracted from the medical record. For analytic purposes, cancer type was grouped as leukemia/lymphoma and solid tumor. Patients were classified as children or eAYAs by age (ages 0-14 or 15-21 years, respectively). This study was approved by the CHLA Institutional Review Board (IRB) with a waiver for informed consent, because only anonymous data were collected, and there was no patient contact.
Determination of CCT Existence, Availability, and Enrollment Status
For the purposes of this study, clinical trial existence was operationalized as a CCT that was appropriate for the patient's age, diagnosis, and stage/risk-group and was registered nationally on clinicaltrials.gov and listed as open and recruiting. Clinical trial availability was operationalized as an existing CCT that was IRB-approved, activated, and open to enrollment at CHLA at the time of that patient's diagnosis. Clinical trial enrollment was operationalized as the patient being successfully entered onto the CCT according to standard procedures of the Clinical Trials Office for the CHLA Children's Center for Cancer and Blood Diseases. With regard to consenting procedures for CCTs, the CHLA IRB requires written informed assent and parental permission for cognitively intact patients ages 7 to 17 years and written informed consent for those aged 18 years. Regardless of patient age, permission for CCT participation is obtained in accordance with these requirements by the disease-specific clinical team.
For each patient, the existence of a CCT was determined by S.M.T. within 2 weeks of receiving the diagnosis by searching clinicaltrials.gov for a relevant CCT. The 2-week timeframe was established because trial sponsors are required to post updates on clinicaltrials.gov within 4 weeks of changes in enrolling status. The diagnosis was entered into the search term area, with studies that were limited to those "open and recruiting," "interventional," and available in the United States. If a trial was so identified, then patient-specific clinical information (eg, histology, stage, grade, risk group, genomic status, and other characteristics) was used to determine the patient's Original Article specific eligibility for that trial. Thus, patients who were confirmed as eligible were classified as having an existing CCT. Trial-specific data available on clinicaltrials.gov were recorded, including the National Clinical Trial (NCT) identification number, phase, categorical type (eg, the National Clinical Trials Network [NCTN], other national collaborative group, multicenter collaboration, industry, or institutional), the specific sponsor (eg, the Children's Oncology Group), and the date the trial opened. Patients with an existing CCT were then assessed for availability of and enrollment onto the CCT, as described above.
For patients who had more than 1 applicable trial listed on clinicaltrials.gov but none available at CHLA, only 1 trial was recorded as existing using the following hierarchy: NCTN, other national collaborative group, multicenter collaboration, industry-sponsored, or institutional.
Statistical Analysis
Descriptive statistics were used to characterize the sample. Differences in demographics, CCT existence, CCT availability, and CCT enrollment among eAYAs versus children were evaluated using the chi-square test of proportions. The effects of demographics and disease characteristics on CCT enrollment were analyzed using logistic regression. Predictor variables, consisting of age, sex, race/ethnicity, ethnicity, and cancer type, were evaluated in univariable models. We tested for 2-way interactions between all predictors, and none were identified. Two multivariable models were assessed, 1 that included ethnicity and 1 that included race/ethnicity, and both models included age, sex and cancer type because of their clinical relevance. The model selected for reporting adjusted for ethnicity, because its effect was stronger than that for race/ethnicity in univariable analysis. All analyses were performed using 2-sided tests, with P values < .05 defined as significant. The Stata statistical software package was used for all analyses (Stata Corporation, College Station, TX). 19 
RESULTS
Between November 1, 2015 and December 1, 2016, in total, 277 unique patients were identified and screened for eligibility (Fig. 1 ). Of these, 61 were excluded for having relapsed disease (n 5 42; 24 children and 18 eAYAs) or because they had already started cancer treatment before they were transferred to CHLA (n 5 19; 13 children and 6 eAYAs). There were no patients who developed subsequent malignant neoplasms.
Patient Characteristics
In total, 216 consecutive patients, including 158 children and 58 eAYAs, constituted the analytic sample ( Table 1) . The median ages of the childhood and eAYA groups were 6 years (range, 0-14 years) and 17 years (range, 15-20 years), respectively. Other demographic characteristics were similar, except there were more males in the eAYA group. In both groups, more than one-half patients were Hispanic, consistent with the population served by CHLA. A significantly higher proportion of diagnoses were leukemia and brain tumors among children, whereas lymphoma and nonbrain solid tumors were more common among eAYAs.
CCT Existence, Availability, and Enrollment Proportions
The proportions of CCT existence, availability, and enrollment were compared between eAYAs and children (Fig. 2) . The proportions of eAYAs and children were similar for having both an existing CCT Table 1 (see online supporting information) indicates that, for both eAYAs and children, a diagnosis of leukemia had the highest proportion of existing and available CCTs, whereas a diagnosis of nonbrain solid tumors had the lowest. However, within diagnoses, there were no compelling age-related differences in CCT existence or availability. For our sample, most diagnoses without an available CCT occurred in both children and eAYAs. These included astrocytoma, Ewing sarcoma (localized), germ cell tumors, Hodgkin lymphoma (low stage), melanoma, mixed phenotypic acute leukemia, neuroblastoma, non-Hodgkin lymphoma, osteosarcoma, rhabdomyosarcoma, and thyroid carcinoma. Among children, diagnoses for which CCTs were not available included chondrosarcoma, chordoma, hepatoblastoma, glioblastoma multiforme, infantile fibrosarcoma, inflammatory myofibroblastic tumor, Langerhans cell histiocytosis, rhabdoid tumor, renal cell carcinoma, retinoblastoma, solid pseudopapillary tumor of the pancreas, synovial sarcoma, transitional liver cell tumor, and undifferentiated sarcoma. There were no diagnoses encountered only among eAYAs for which no CCT was available.
Predictors of CCT Enrollment
Logistic regression analysis was used to evaluate predictors both for overall CCT enrollment (ie, among all patients included in the study; n 5 216) and for CCT enrollment when the existing trial was also available at CHLA (n 5 98). For overall CCT enrollment (Table 2 ), univariable analysis indicated that there was a significantly lower likelihood (eAYAs: odds ratio [OR], 0.30; 95% confidence interval [CI], 0.13-0.70; P 5 .002) for patients who were diagnosed with solid tumors (OR, 0.09; 95% CI, 0.04-0.22; P .001) to be enrolled, whereas there was a significantly greater likelihood for Hispanic patients to be enrolled compared with non-Hispanic patients (OR, 2.09; 95% CI, 1.10-3.95; P 5 .021). In multivariable analysis adjusted for sex, ethnicity, cancer type, and age, overall CCT enrollment was significantly less likely to occur both for eAYAs (OR, 0.22; 95% CI, 0.09-0.58; P 5 .001) and for patients diagnosed with solid tumors (OR, 0.07; 95% CI, 0.03-0.18; P .001). In contrast, among those for whom existing CCTs were available at CHLA (Table 3) , the only factor associated with CCT enrollment was age: eAYAs were significantly less likely to be enrolled in both univariable (OR, 0.22; 95% CI, 0.08-0.60; P 5 .002) and multivariable (OR, 0.21; 95% CI, 0.07-0.61; P 5 .003) analyses. Predictors of enrollment within the eAYA group could not be assessed because of small numbers.
CCT Characteristics
The characteristics of the CCTs that existed, were available, and were used for enrollment are summarized in Table 4 and in Supporting Table 1 (see online supporting information). Twenty-six unique trials existed for the patients in this study, including 20 for children and 12 for eAYAs; and 6 trials spanned both age groups (leukemia, 4 trials; lymphoma, 1 trial; and solid tumors, 1 trial). Of these, 13 trials were available locally, compared with 7 for eAYAs. The target cancers addressed by these trials were similar across both age groups, except that children had more brain tumor studies available. Phase 3 trials accounted for the vast majority of available trials in both age groups. For both age groups, most trials were sponsored by the NCTN; all of the available phase 3 trials were sponsored by the Children's Oncology Group. Among children, all 5 of the existing single-institution studies were sponsored by a single pediatric cancer research hospital; whereas, among AYAs, both existing single-institution studies were from adult-focused cancer research centers. Within phases and types of CCTs, the distribution of patients by age was not appreciably different (Supporting Table 1 ; see online supporting information).
DISCUSSION
The overall objective of this study was to evaluate the relative importance of trial availability as a cause of underenrollment of eAYAs onto CCTs. Consistent with our hypothesis, we observed that, compared with children, a significantly lower proportion of eAYAs was enrolled onto existing national CCTs. However, contrary to our hypothesis, we also observed that there was no significant difference in CCT availability among children and eAYAs. It is noteworthy that, among those patients who had a CCT available, a significantly lower proportion of eAYAs was enrolled. To our knowledge, this is the first study to evaluate potential differences in CCT availability and their impact on CCT enrollment for eAYAs versus children. Our principal finding of lower eAYA enrollment in, but equivalent availability of, CCTs is consequential, because it indicates that factors other than CCT availability serve as barriers to eAYA enrollment. The current study addresses a clinically important issue, because low CCT enrollment of AYAs has been correlated with poorer cancer survival improvement. 12 To date, explaining low AYA participation in CCTs has been the subject of considerable speculation but limited research. In this study, we focused on potential differences in CCT availability. Several authors have argued that there are an insufficient number and variety of CCTs available for the cancers that are most common among AYAs and that opening more trials should be a high priority. 9, 16, 17 This is a crucial question, because many factors that influence enrollment become relevant only when a CCT is available. However, in the current study, there was no difference in the proportion of eAYAs and children for whom a CCT either existed at the national level or was available within our institution. Conversely, the proportion of those eAYAs who actually enrolled onto available CCTs was less than one-half that of children. In adjusted multivariable analysis, eAYAs were nearly 80% less likely to be enrolled. Few literature reports exist to provide a context for these findings. A recent children's hospitalbased, retrospective study reported that 62% of eAYAs, versus 47% of children, lacked an available CCT, which had not improved from a previous study.
11 ,17 In a large, retrospective, case-linked study of CCT enrollment performed in our cancer center that documented markedly lower CCT enrollment of AYAs compared with children, we observed that, for the top 10 diagnoses in each age group, AYAs had 8 available CCTs compared with 10 for children. 10 In contrast to those 2 studies, a Surveillance, Epidemiology, and End Results-based study of AYA CCT enrollment by the NCI estimated that actual enrollment exceeded expected enrollment for several cancer types. 18 All 3 of these studies reflect the difficulty of retrospectively collecting robust CCT enrollment data. To our knowledge, no published study to date has used prospective, case-linked methodology to assess the impact of CCT availability on AYA enrollment. This approach offers substantial benefits. For example, we discerned that, although fewer CCTs did in fact exist for eAYAs than for children (12 vs 20 CCTs, respectively), the proportions of patients who had CCTs available were equivalent. For discussions of CCT availability, this illustrates the importance of accounting for site and patient characteristics in addition to the absolute number of existing trials.
The setting and design of our study afforded important strengths with some limitations. A significant strength was prospective case ascertainment combined with real-time, patient-specific evaluation of CCT existence and availability. This provided a level of accuracy that is difficult to achieve in retrospect. The volume and heterogeneity of patients at CHLA made it feasible to conduct this study over a relatively short period at a single institution, yet the sample was not large enough to assess definitively all covariates of interest. For example, Hispanic ethnicity was suggestive of facilitating CCT enrollment in our adjusted multivariable analysis, a finding consistent with our previous retrospective study, 10 but did not reach statistical significance. Also, results obtained at a large, urban, academic children's hospital may be different from those obtained in either a community-based setting, where many AYAs are treated, or at an academic hospital serving the full AYA age spectrum. [20] [21] [22] Similarly, our sample, with a maximum age of 21 years, may not be reflective of CCT activity among older AYAs. Our focus on patients with first cancers limits our ability to comment on the impact of CCT availability in those with relapsed cancer, which could be important for AYAs, who often have high-risk disease. Finally, we relied on pathology specimens to trigger case ascertainment, which could have resulted in missing a small number of patients for whom diagnosis is based on imaging, such as those with diffuse intrinsic pontine glioma.
Nonetheless, our study offers important insights concerning barriers and facilitators of CCT enrollment among AYAs. What implications should be drawn from these data? First, it is clear that factors other than CCT availability influence AYA enrollment and need further study. These downstream factors may include provider-level choices not to present the CCT option because of medical and perceived social circumstances, limited professional time, poor reimbursement, and lack of research infrastructure. 23, 24 At the patient level, several psychosocial factors may influence AYA enrollment, including coping status, perceptions of clinical research, informed consent issues, and social relationships. [25] [26] [27] Because our study was not designed to capture such information, further research is needed to understand and address these factors.
Second, because the current results indicate that only about one-half of both children and eAYAs had existing CCTs, there may indeed be opportunities to increase the number of CCTs for both age groups. Our data do not provide a clear indication of where such efforts should be focused, because the diagnoses for which CCTs were not available spanned the spectrum of age, incidence, and outcomes. Thus, for improving survival, it seems reasonable to maximize CCT availability for the more common, highest risk cancers. However, this seems unlikely to be an effective stand-alone strategy for improving AYA-specific CCT enrollment. Similarly, with a high proportion of existing trials already locally available, our results suggest that broad efforts to increase CCT activation at the site level may not necessarily yield higher enrollment for either age group. Conversely, it must be acknowledged that some institutions may face substantial resource limitations, which could prevent the activation of all CCTs. Also, the number of existing CCTs nationally may fluctuate over time, because they are individually launched and completed. Therefore, it is safe to assume that maximizing both development and availability of impactful CCTs for AYAs will always be necessary and appropriate.
Finally, because this study reflects the CCT enrollment fate only of those patients who "made it through the door" at CHLA, it does not negate the importance of prehospital barriers that impede AYA CCT participation. 9, 20, 21 Thus, the most important finding of this study is that, for AYAs, future research should be focused on provider-level and patient/family-level factors affecting CCT enrollment. These factors are the subject of a funded study we are now conducting.
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